Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $11.47 million. The enterprise value is $127.33 million.
Important Dates
The next estimated earnings date is Friday, May 22, 2026, after market close.
| Earnings Date | May 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 18.72 million shares outstanding. The number of shares has increased by 171.15% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 18.72M |
| Shares Change (YoY) | +171.15% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 3.02% |
| Owned by Institutions (%) | 4.04% |
| Float | 14.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.24 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.03
| Current Ratio | 1.03 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -9.46% |
| Return on Invested Capital (ROIC) | -24.82% |
| Return on Capital Employed (ROCE) | -21.99% |
| Weighted Average Cost of Capital (WACC) | 8.58% |
| Revenue Per Employee | $121,122 |
| Profits Per Employee | -$91,910 |
| Employee Count | 401 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, Trinity Biotech has paid $958,000 in taxes.
| Income Tax | 958,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.56% in the last 52 weeks. The beta is 0.79, so Trinity Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -13.56% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 40.59 |
| Average Volume (20 Days) | 111,514 |
Short Selling Information
The latest short interest is 402,865, so 3.82% of the outstanding shares have been sold short.
| Short Interest | 402,865 |
| Short Previous Month | 291,283 |
| Short % of Shares Out | 3.82% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.19 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $48.57 million and -$36.86 million in losses. Loss per share was -$1.49.
| Revenue | 48.57M |
| Gross Profit | 17.87M |
| Operating Income | -15.22M |
| Pretax Income | -35.33M |
| Net Income | -36.86M |
| EBITDA | -14.03M |
| EBIT | -15.22M |
| Loss Per Share | -$1.49 |
Full Income StatementBalance Sheet
The company has $1.34 million in cash and $117.20 million in debt, giving a net cash position of -$115.86 million or -$6.19 per share.
| Cash & Cash Equivalents | 1.34M |
| Total Debt | 117.20M |
| Net Cash | -115.86M |
| Net Cash Per Share | -$6.19 |
| Equity (Book Value) | -54.72M |
| Book Value Per Share | -2.93 |
| Working Capital | 1.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.10 million and capital expenditures -$256,000, giving a free cash flow of -$1.36 million.
| Operating Cash Flow | -1.10M |
| Capital Expenditures | -256,000 |
| Depreciation & Amortization | 1.19M |
| Net Borrowing | 7.01M |
| Free Cash Flow | -1.36M |
| FCF Per Share | -$0.07 |
Full Cash Flow StatementMargins
Gross margin is 36.78%, with operating and profit margins of -31.33% and -75.88%.
| Gross Margin | 36.78% |
| Operating Margin | -31.33% |
| Pretax Margin | -72.73% |
| Profit Margin | -75.88% |
| EBITDA Margin | -28.88% |
| EBIT Margin | -31.33% |
| FCF Margin | n/a |